Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. on April 27, 2015. The report discloses corporate governance actions regarding executive compensation approved by the Compensation Committee of the Board of Directors, effective May 1, 2015. Note: The request metadata references "Altimmune, Inc.," but the filing text explicitly identifies the registrant as PharmAthene, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The material change reported is the approval of new compensatory arrangements for two senior officers:
- Jeffrey Jones, Ph.D. (Vice President and Chief Operating Officer): Eligible for an annual cash bonus of up to 50% of base salary based on performance milestones. Severance includes nine months of base salary continuation and benefits if terminated without cause or resigning for good reason.
- Philip MacNeill (Vice President, CFO, Treasurer, and Secretary): Eligible for an annual cash bonus of up to 25% of base salary based on performance milestones.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are disclosed in this document other than the standard terms of the executive employment agreements.
Investor Verification Checklist
- Verify the correct registrant name (PharmAthene, Inc.) versus the metadata reference (Altimmune, Inc.).
- Review the specific performance milestones required to trigger the 50% and 25% bonus payouts.
- Confirm the total base salary figures for Dr. Jones and Mr. MacNeill to calculate potential maximum bonus liabilities.
- Check subsequent filings for any changes to these compensation terms or executive departures.